For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
- Ono Files NDA for Nivolumab for Malignant Melanoma
December 27, 2013
- MSD Files NDA for Vaniprevir for Chronic Hepatitis C
December 27, 2013
- Kissei Grants US Pfizer Worldwide Exclusive Rights for Gout and Hyperuricemia Treatment KUX-1151 Outside Japan
December 26, 2013
- Meiji Seika Pharma Scraps Codevelopment Deal with Danish Biotech
December 26, 2013
- Takeda to License Inflammatory Bowel Disease Treatment from US Biotech
December 25, 2013
- Tenelia Now Indicated for Type 2 Diabetes Without Concurrent Use Restrictions
December 25, 2013
- SSI Said Ex-Employee Manipulated Data of Anti-Obesity Drug Study
December 25, 2013
- Daiichi Sankyo Files Edoxaban for AF, VTE New Indications
December 25, 2013
- Kyowa Kirin, LEO Pharma Collaborate to Market Fixed-Dose Combination Topical Treatment for Psoriasis in Japan
December 24, 2013
- Shire Names NBI Operating Officer Sunohara as New Japan Head
December 20, 2013
- Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
- Can Epadel Continue to Maintain Sales in the Face of Competition from Lotriga and Generics?
December 20, 2013
- UMN, API, Yakult Conclude Another Joint Biosimilar Business Agreement in Oncology Field
December 19, 2013
- Astellas, Nichi-Iko Conclude Definitive Agreement on Transfer of Fuji Plant
December 19, 2013
- ViiV Healthcare, Shionogi Seal Copromotion Deal for Anti-HIV Treatment Dolutegravir
December 18, 2013
- Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…